Thomas E. Malcolm, PhD

Gene Editing, Cell Therapy, Infectious Disease

Thomas E. Malcolm is providing advice on Gene Editing, Cell Therapy and Infectious Disease to FPG with respect to clinical and scientific matters related to current and prospective clients.

Dr. Malcolm currently serves as COO and CTO for Kermode Biotechnologies In New York and its sister company Excidus Biotechnologies in China, respectively. As a co-founder and Board Member he helps to guide the company’s mission to protect livestock and household animals from pathogens using genetically modified gene editing and antibody vaccine development approaches.

Dr. Malcolm is also a consultant for Aridis Pharmaceuticals, a CRISPR-based antibody vaccine development company, located in California. Tom serves as a scientific advisor for BioMark Diagnostics Inc., a company developing metabolomic diagnostics.

Dr. Malcolm served as the CEO and CSO of Excision Biotherapeutics Inc., CRISPR company that he founded, focused on CRISPR gene editing for the treatment of human viral infectious diseases. Dr. Malcolm also founded Criterion BioScience Research Group in 2012, a life sciences advisory group looking at emergent biotechnologies.

Dr. Malcolm has published his work on viruses and cancers in multiple high impact journals. He is also a co-inventor on numerous patents.. Tom earned his Ph.D. in Biochemistry and Molecular Biology from the University of British Columbia, Vancouver, Canada.